Hexadecanoic acid;hexane-1,2,3,4,5,6-hexol

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Hexadecanoic acid;hexane-1,2,3,4,5,6-hexol
• 英文别名: hexadecanoic acid;hexane-1,2,3,4,5,6-hexol
• 化学式: C22H46O8
• 分子量: 438.6
• InChiKey: NSZWQJSPGLSSNU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.97
• 重原子数：
  30
• 可旋转键数：
  19
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  159
• 氢给体数：
  7
• 氢受体数：
  8

文献信息

• [EN] PHARMACEUTICAL FORMULATIONS COMPRISING 6-CHLORO-7-(4-(4-CHLOROBENZYL)PIPERAZIN-1 -YL)-2-(1,3-DIMETHYL-1 HPYRAZOL-4-YL)-3H- IMIDAZO[4,5-B]PYRIDINE<br/>[FR] FORMULATIONS PHARMACEUTIQUES COMPRENANT DU 6-CHLORO-7-(4-(4-CHLOROBENZYL)PIPÉRAZIN-1-YL)-2-(1,3-DIMÉTHYL-1 HPYRAZOL-4-YL)-3 H-IMIDAZO[4,5-B]PYRIDINE
  申请人：ELLIPSES PHARMA LTD

  公开号：WO2021176214A1

  公开（公告）日：2021-09-10

  The present invention relates to formulations comprising a compound of Formula (1) (6-chloro-7-(4-(4- chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine) which is an inhibitor of Aurora kinase enzyme activity and FMS-like tyrosine kinase 3 (FLT3) activity, and a non-ionic surfactant. The present invention also relates to processes for the preparation of the formulations of the compound, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which Aurora kinase and/or FLT3 activity is implicated.